Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Background: The combination of an inhaled corticosteroid (ICS) and a long-acting bronchodilator is recommended in the treatment of patients with chronic obstructive pulmonary disease (COPD) who have frequent exacerbations. Budesonide/formoterol dry powder inhaler (DPI) has demonstrated efficacy and tolerability in patients with COPD.
Objective: To evaluate the efficacy and tolerability of budesonide/formoterol administered via one hydrofluoroalkane pressurized metered-dose inhaler (pMDI) in patients with COPD.
Methods: This was a 6-month, randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicentre study (NCT00206154) of 1704 patients aged ≥40 years with moderate to very severe COPD conducted in 194 centres in the US, Czech Republic, the Netherlands, Poland and South Africa. After 2 weeks of treatment based on previous therapy (ICSs and short-acting bronchodilators allowed during the run-in period), patients received one of the following treatments administered twice daily: budesonide/formoterol pMDI 160/4.5 μg × two inhalations (320/9 μg); budesonide/formoterol pMDI 80/4.5 μg × two inhalations (160/9 μg); budesonide pMDI 160 μg × two inhalations (320 μg) plus formoterol DPI 4.5 μg × two inhalations (9 μg); budesonide pMDI 160 μg × two inhalations (320 μg); formoterol DPI 4.5 μg × two inhalations (9 μg); or placebo.
Main outcome measures: The co-primary efficacy variables were pre-dose forced expiratory volume in 1 second (FEV1) and 1-hour post-dose FEV1.
Results: Budesonide/formoterol 320/9 μg demonstrated significantly greater improvements in pre-dose FEV1 versus formoterol (p = 0.026; pre-specified primary comparator) and 1-hour post-dose FEV1 versus budesonide (p < 0.001; pre-specified primary comparator); budesonide/formoterol 160/9 μg demonstrated significantly greater improvements versus budesonide (p < 0.001) for 1-hour post-dose FEV1 but not versus formoterol for pre-dose FEV1. Dyspnoea (measured using the Breathlessness Diary) and health-related quality-of-life (HR-QOL) scores (based on the St George’s Respiratory Questionnaire total score) were significantly improved with both dosage strengths of budesonide/formoterol compared with budesonide, formoterol and placebo (p ≤ 0.044 for all). Although not powered a priori for comparisons, the number of exacerbations per patient-treatment year requiring treatment with oral corticosteroids and/or hospitalization was numerically (20–25%) lower with the budesonide-containing treatments (0.710–0.884) versus formoterol (1.098) and placebo (1.110). This result was driven by the exacerbations requiring treatment with oral corticosteroids (79–120 events). The number of exacerbations resulting in hospitalization was very low across treatment groups (11–22); the number per patient-treatment year was significantly different for budesonide/formoterol 320/9 μg (0.158) versus other treatment groups (0.081–0.108) except budesonide/formoterol 160/9 μg (0.139), and for budesonide/formoterol 160/9 μg versus formoterol (0.081) [p ≤ 0.05]. All treatments were generally well tolerated. The incidence of individual non-fatal serious adverse events was similar across all treatment groups, except COPD, which was highest in the budesonide/formoterol 320/9 μg group (6.1%) and lowest in the budesonide (3.6%) and formoterol (3.9%) groups, with a range of 4.3–4.6% in the budesonide/formoterol 160/9 μg, budesonide plus formoterol and placebo groups. Budesonide/formoterol had a safety profile comparable with that of the monocomponents and placebo. There was no increase in the incidence of pneumonia in the active treatment groups relative to placebo.
Conclusions: Budesonide/formoterol pMDI 320/9 μg demonstrated significantly greater efficacy for pulmonary function on both co-primary endpoints versus the pre-specified comparators (formoterol DPI 9 μg for pre-dose FEV1 and budesonide pMDI 320 μg for 1-hour post-dose FEV1). Budesonide/formoterol pMDI 160/9 μg demonstrated significantly greater efficacy for 1-hour post-dose FEV1 versus budesonide pMDI 320 μg. Dyspnoea scores and HR-QOL were significantly improved with both budesonide/formoterol pMDI dosage strengths versus both monocomponents and placebo. Both budesonide/formoterol pMDI dosage strengths were well tolerated relative to the monocomponents and placebo.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: updated 2007 [online]. Available from URL: http://www.goldcopd.com [Accessed 2008 Feb 12]
- Aalbers, R, Ayres, J, Backer, V (2002) Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 19: pp. 936-43 CrossRef
- Dahl, R, Greefhorst, LAPM, Nowak, D (2001) Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: pp. 778-84
- Mahler, DA, Donohue, JF, Barbée, RA (1999) Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 115: pp. 957-65 CrossRef
- Rennard, SI, Anderson, W, Zuwallack, R (2001) Use of a longacting β2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 163: pp. 1087-92
- Wadbo, M, Löfdahl, C-G, Larsson, K (2002) Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study. Eur Respir J 20: pp. 1138-46 CrossRef
- Alsaeedi, A, Sin, DD, McAlister, FA (2002) The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 113: pp. 59-65 CrossRef
- Burge, PS, Calverley, PM, Jones, PW (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 320: pp. 1297-303 CrossRef
- Gartlehner, G, Hansen, RA, Carson, SS (2006) Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med 4: pp. 253-62 CrossRef
- Sin, DD, Tu, JV (2001) Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164: pp. 580-4
- Sin, DD, Man, SFP (2003) Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: does the dose matter?. Eur Respir J 21: pp. 260-6 CrossRef
- Soriano, JB, Vestbo, J, Pride, NB (2002) Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20: pp. 819-25 CrossRef
- Calverley, PMA, Anderson, JA, Celli, B f t (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356: pp. 775-89 CrossRef
- Sutherland, ER (2007) Inhaled steroids and outcomes in COPD: progressing beyond FEV1. Chest 131: pp. 648-9 CrossRef
- Soriano, JB, Sin, DD, Zhang, X (2007) A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest 131: pp. 682-9 CrossRef
- Halpin, D (2008) Mortality in COPD: inevitable or preventable? Insights from the cardiovascular arena. COPD 5: pp. 187-200 CrossRef
- Calverley, PM, Boonsawat, W, Cseke, Z (2003) Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22: pp. 912-9 CrossRef
- Szafranski, W, Cukier, A, Ramirez, A (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21: pp. 74-81 CrossRef
- Eltayara, L, Becklake, MR, Volta, CA (1996) Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154: pp. 1726-34
- Miller, CJ, Senn, S, Mezzanotte, WS (2008) Bronchodilation of formoterol administered with budesonide: device and formulation effects. Contemp Clin Trials 29: pp. 114-24 CrossRef
- Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152: pp. 1107-36
- Crapo, RO, Morris, AH, Gardner, RM (1981) Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 123: pp. 659-64
- Leidy, NK, Schmier, JK, Jones, MK (2003) Evaluating symptoms in chronic obstructive pulmonary disease: validation of the Breathlessness, Cough, and Sputum Scale. Respir Med 97: pp. S59-70 CrossRef
- Leidy, NK, Wyrwich, KW (2005) Bridging the gap: using triangulation methodology to estimate minimal clinically important differences (MCIDs). COPD 2: pp. 157-65 CrossRef
- Jones, PW, Spencer, S, Adie, S (2003) The St George’s Respiratory Questionnaire manual, Version 2. 1. Respiratory Medicine, St. George’s, University of London, London
- Jones, PW, Quirk, FH, Baveystock, CM (1992) A self-complete measure of health status for chronic airflow limitation. The St George’s Respiratory Questionnaire. Am Rev Respir Dis 145: pp. 1321-7
- Jones, PW (2005) St George’s Respiratory Questionnaire: MCID. COPD 2: pp. 75-9 CrossRef
- Mahler, DA, Wire, P, Horstman, D (2002) Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 166: pp. 1084-91 CrossRef
- Calverley, P, Pauwels, R, Vestbo, J f t (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361: pp. 449-56 CrossRef
- Kardos, P, Wencker, M, Claab, T (2007) Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175: pp. 144-9 CrossRef
- Wedzicha, JA, Calverley, PMA, Seemungal, TA (2008) The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177: pp. 19-2 CrossRef
- Efficacy and Safety of Budesonide and Formoterol in One Pressurized Metered-Dose Inhaler in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Volume 68, Issue 14 , pp 1975-2000
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
- Author Affiliations
- 1. David Geffen School of Medicine at UCLA, Division of Pulmonary and Critical Care Medicine, University of California, 10833 Le Conte Avenue, Los Angeles, California, 90095-1690, USA
- 2. University of Nebraska Medical Center, Omaha, Nebraska, USA
- 3. AstraZeneca LP, Wilmington, Delaware, USA